Exploiting molecular targets in pancreatic cancer.
Oncology has entered an era of molecular therapy. Given the multitude of molecular defects involved with pancreatic carcinogenesis, invasion, and metastasis, it is unlikely that single-agent targeted therapy will alter the course of this disease. Given the emergence of molecular targets and a growing number of agents available for clinical development, however, meaningful improvements in patient outcomes are expected, particularly if treatments are designed and delivered rationally.
Wolff
Robert A
RA
Department of Gastrointestinal Medical Oncology, University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 426, Houston, TX 77030-4095, USA. rwolff@mdanderson.org
D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D017209:Apoptosis / Q000187:drug effects; D018797:Cell Cycle Proteins / Q000187:drug effects; D000068818:Cetuximab; D017326:Clinical Trials, Phase III as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000276:immunology; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D061965:Matrix Metalloproteinase Inhibitors; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases; D016283:Proto-Oncogene Proteins p21(ras) / Q000037:antagonists & inhibitors; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000276:immunology; D012107:Research Design; D015398:Signal Transduction / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases; D000068878:Trastuzumab; D016159:Tumor Suppressor Protein p53 / Q000502:physiology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018797:Cell Cycle Proteins; D000068818:Cetuximab; D004791:Enzyme Inhibitors; D066246:ErbB Receptors; D006877:Hydroxamic Acids; D061965:Matrix Metalloproteinase Inhibitors; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases; D016283:Proto-Oncogene Proteins p21(ras); D020794:Receptor Protein-Tyrosine Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; D058570:TOR Serine-Threonine Kinases; D000068878:Trastuzumab; D016159:Tumor Suppressor Protein p53; C100342:marimastat; C546842:MTOR protein, human; C501009:HRAS protein, human